e10vq

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010


o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File number 0-935

CYTOCORE, INC.

(Exact Name of Registrant as Specified in Its Charter)



Delaware		36-4296006

(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

414 North Orleans Street, Suite 510
Chicago, IL 60654

(Address of Principal Executive Offices)

(312) 222-9550

(Registrant’s Telephone Number, including Area Code)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes o No o (not required)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rue 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer o

Accelerated Filer o

Non-Accelerated Filer o
(Do not check if a smaller reporting company)

Smaller Reporting Company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

The number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

COMMON STOCK, $0.001 PAR VALUE, AT NOVEMBER 15, 2010: 46,135,083

PART I. — FINANCIAL INFORMATION

Item 1. Financial Statements

CYTOCORE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Dollars in thousands)


	September 30,			December 31,
	2010			2009
Assets
Current Assets:
Cash and cash equivalents	$	6		$	—
Accounts receivable		11			17
Inventories		569			574
Prepaid expenses and other current assets		10			44

Total current assets		596			635

Fixed assets, net		1,552			1,846
Licenses, patents and technology, net of amortization		86			62
Inventories, non-current		325			325

Total assets	$	2,559		$	2,868


Liabilities and Stockholders’ Deficit
Current Liabilities:
Checks issued in excess of amounts on deposit	$	—		$	5
Accounts payable		1,886			2,102
Accrued payroll costs		1,317			818
Advances payable to related parties		1,551			763
Accrued expenses		555			1,225
Derivative liability		161			—
Notes payable		199			70

Total current liabilities		5,669			4,983


Stockholders’ Deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 373,555 shares issued and outstanding at September 30, 2010 and December 31, 2009 (Liquidation value of all classes of preferred stock $2,876 at September 30, 2010)		1,492			1,492
Common stock, $0.001 par value; 500,000,000 shares authorized; 46,135,083 and 42,173,810 shares issued and 46,115,874 and 42,154,601 shares outstanding at September 30, 2010 and December 31, 2009, respectively		46			42
Additional paid-in-capital		92,408			92,106
Treasury stock: 19,209 shares at September 30, 2010 and December 31, 2009		(327	)		(327	)
Accumulated deficit		(96,652	)		(95,351	)
Accumulated comprehensive loss—
Cumulative translation adjustment		(77	)		(77	)

Total stockholders’ deficit		(3,110	)		(2,115	)

Total liabilities and stockholders’ deficit	$	2,559		$	2,868

See accompanying notes to these condensed consolidated financial statements.

CYTOCORE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)


	Nine months ended						Three months ended
	September 30,						September 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)

Net revenues	$	24		$	28		$	8		$	5

Operating expenses

Cost of revenues		1			6			1			—
Research and development		213			300			83			87
Selling, general and administrative, (net of settlement of trade debt of $71 for the nine and three months ended September 30, 2010)		1,297			2,381			495			525


Total operating expenses		1,511			2,687			579			612


Operating loss		(1,487	)		(2,659	)		(571	)		(607	)

Other income (expense)

Provision for legal settlement		—			(948	)		—			—
Benefit from derivative liability		238			—			56			—
Interest expense		(52	)		(29	)		(23	)		(3	)

Total other income (expense)		186			(977	)		33			(3	)


Net loss		(1,301	)		(3,636	)		(538	)		(610	)

Preferred stock dividend		—			—			—			—


Net loss applicable to common stockholders	$	(1,301	)	$	(3,636	)	$	(538	)	$	(610	)


Basic and diluted net loss per common share	$	(0.03	)	$	(0.09	)	$	(0.01	)	$	(0.01	)


Basic and diluted weighted average number of common shares outstanding		44,939,579			41,925,232			45,477,839			42,173,810

See accompanying notes to these condensed consolidated financial statements.

CYTOCORE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Dollars in thousands)


	Nine Months Ended
	September 30,
	2010			2009
Operating Activities:
Net loss	$	(1,301	)	$	(3,636	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		370			355
Amortization of discount		41			—
Stock issued to non-employees for services		6			5
Common stock issued for compensation expense		15			—
Non-cash compensation expense		1			2
Non-cash interest related to warrant modification		—			21
Gain on settlement of trade debt		(71	)		—
Benefit from derivative liability		(238	)		—
Non-cash charge for legal settlement		—			948
Stock to be issued for directors fees		—			350
Changes in assets and liabilities:
Checks issued in excess of amounts on deposit		(5	)		—
Accounts receivable		5			24
Inventories		5			(135	)
Prepaid expenses and other current assets		34			2
Accounts payable		(142	)		135
Accrued expenses		399			522


Net cash used in operating activities		(881	)		(1,407	)


Investing activities:
Purchase of license		(36	)		(50	)


Net cash used in investing activities		(36	)		(50	)
Financing activities:
Proceeds from related parties		798			637
Proceeds from issuance of convertible note		75			—
Proceeds from sale of common stock		50			—
Proceeds from exercise of warrants		—			270


Net cash provided by financing activities		923			907


Net increase (decrease) in cash and cash equivalents		6			(550	)

Cash and cash equivalents at the beginning of period		—			553


Cash and cash equivalents at end of period	$	6		$	3


Supplemental disclosure of cash flow information:

Non-cash transactions during the period for:
Issuance of common stock and warrants in settlement of a lawsuit	$	538		$	—
Payment of accrued wages with common stock		—			31
Stock issuable for accrued liability		46			—
Warrants exercised with debt in satisfaction of related party advances and other liabilities		—			168
Payment of directors fees with common stock		—			195
Note payable issued in payment of accounts payable resulting in a gain of approximately $71,000		69			—
The Company recorded a derivative liability resulting from potential excess shares and a reduction in additional paid in capital		345			—

See accompanying notes to these condensed consolidated financial statements.

CYTOCORE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Tabular data in thousands, except per share amounts)
(Unaudited)

Note 1. Organization

CytoCore, Inc. (“CCI” or the “Company”) was incorporated in Delaware in December 1998. Except where the context otherwise requires, “CCI,” the “Company,” “we” and “our” refers to CytoCore, Inc. and our subsidiaries and predecessors.

Our current product which we have for sale and have inventory on hand is the SoftPAP^®. CCI is developing, identifying markets to and plans to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the CytoCore SolutionsÔ trade name. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), and patient treatment and monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer Including CCI’s SoftPAP — a cell collection device intended to replace the brush and spatula currently used to collect cervical cytology samples. CCI plans that this focus will later be expanded to include other gynecological cancers as well as bladder, lung and breast cancers, among others. Within each of these markets, CCI anticipates that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations.

The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement CCI’s business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about CCI’s ability to continue as a going concern. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to increase sales of its products, develop new products, and raise additional capital. At September 30, 2010, the Company had cash on hand totaling $6,000, and does not have sufficient cash on hand to fund its operations.

If the Company is unable to obtain adequate additional financing or generate sufficient sales revenues, it will be unable to continue its product development efforts and other activities and will be forced to curtail or cease operations. The consolidated financial statements presented herein do not include any adjustments that might result from the outcome of this uncertainty.

Note 2. Basis of Presentation

The consolidated financial statements for the periods ended September 30, 2010 and 2009 included herein are unaudited. Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature except the issuance of common stock and warrants in settlement of a lawsuit as described in Note 10. and the derivative liability described in Note 9. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2010 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as filed with the SEC.

There was no comprehensive income or loss in the periods presented.

Note 3. Inventory

Inventory consists of the following:


	September 30,		December 31,
	2010		2009
	(unaudited)

Purchased parts	$	270	$	272
Finished goods		624		627

Total inventory		894		899
Less: inventory non-current		325		325

Total inventory current	$	569	$	574

Inventory is valued at the lower of cost or market, using the first in, first out method. Due to the uncertainty as to the timing of sales, the Company has classified $325,000 of inventory as non-current. Additionally, as required by FASB ACS 330-10-30-7, items such as idle facility expense, excessive spoilage, freight, handling costs and re-handling costs are recognized as current period charges. The allocation of fixed production overheads to the costs of conversion are based upon the normal capacity of the production facility. Fixed overhead costs associated with idle capacity are expensed as incurred.

Note 4. Fixed Assets

Fixed assets consist of the following:


	September 30,			December 31,
	2010			2009
	(unaudited)

Furniture and fixtures	$	47		$	47
Laboratory equipment		508			508
Computer and communications equipment		261			261
Design and tooling		1,204			1,204
Machinery and equipment		777			777
Construction in progress		399			399

		3,196			3,196
Less accumulated depreciation and amortization		(1,644	)		(1,350	)

Total	$	1,552		$	1,846

For the nine months ended September 30, 2010 and 2009, depreciation expense was $295,000 and $280,000, respectively. The Company did not allocate any of the depreciation expense of the machinery and equipment or the design and tooling into inventory since the Company has suspended manufacturing. This depreciation was included as a selling, general and administrative expense as excess idle time.

During 2009, a supplier filed suit against CCI alleging that the Company owes it approximately $377,000. This supplier had previously placed a lien on all of the Company’s machinery and equipment. See Note 10 -Legal Proceedings for additional information regarding this claim.

Note 5. Licenses, Patents, and Technology

Licenses, patents, and technology include the following:


	September 30,		December 31,
	2010		2009
	(unaudited)

Licenses	$	320	$	220
Patent costs		133		133
LabCorp Technology Agreement		260		260

		713		613


	September 30,			December 31,
	2010			2009
	(unaudited)

Less accumulated amortization		(627	)		(551	)

Total	$	86		$	62

During 2008, the Company purchased a license for certain technology for an initial total of $200,000. In addition, CCI is obligated to make future payments totaling $100,000 upon obtaining certain milestones under the agreement. During the nine months ending September 30, 2010, CCI made payments of $36,000 and is obligated to make eight additional monthly payments of $8,000 on this liability. The Company is amortizing the initial license over its estimated useful life of two years, and will amortize the additional payments over one year.

Note 6. Accrued Expenses

Accrued expenses include the following:


	September 30,		December 31,
	2010		2009
	(unaudited)

Accrued interest	$	56	$	363
Provision for legal settlement		—		220
Accrued franchise and other taxes		241		214
Accrued compensation		75		40
Other accrued expenses		183		388

Total	$	555	$	1,225

Note 7. Notes Payable and Advances-related parties

Notes payable to unrelated parties consist of:


	September 30,			December 31,
	2010			2009
	(unaudited)

Asher Enterprises, Inc., $75,000 Convertible Promissory Note issued March 9, 2010; interest rate 8% per annum, due December 10, 2010	$	75		$	—

Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum, due December 20, 2001		15			15

Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest rate 8% per annum payable after December 31, 2003		21			21

White White & Van Etten PC, $68,750 non-interest bearing Promissory Note issued September 30, 2010; payable in eleven equal payments of $6,250; due August 24, 2011		67			—

Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; Interest rate Canadian Prime plus 6% per annum, due December 27, 1999; represents a debt of AccuMed		34			34

Less discount		(13	)		—

	$	199		$	70

On September 30, 2010, the Company made a settlement with White White & Van Etten (“White”), CCI owed White $140,000. As a result of this settlement, CCI issued a non-interest bearing Promissory Note for $68,750 payable in 11 monthly payment of $6,250 and White forgave the remaining $71,000. The Company recorded the benefit as a reduction of selling, general and administration expense. The CCI also imputed interest totaling $2,000 on this note at the rate of 5% per annum and will amortize the interest over the term of the note.

In March 2010, the Company received $75,000 in exchange for a Convertible Promissory Note payable to Asher Enterprises, including unpaid interest, and is convertible into unregistered, restricted common stock at any time. The note bears interest at 8% and is unsecured. The conversion price is variable and is determined as 58% of the average of the lowest three trading prices during the ten trading day period prior to the conversion notice. As a

result, the Company has recorded a discount of $55,000 and a liability equal to the fixed monetary amount known at inception for the conversion option. The discount will be amortized over the term of the note using the effective interest method. Upon issuance of the shares to settle the liability, equity will be increased by the amount of the liability and no gain or loss will be recognized or any difference between the fixed monetary amount known at inception and the ending market price. CCI recorded a charge of $41,000 for amortization of the discount and recorded the charge against the derivative liability.

The Company has failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above, except for Asher Enterprises. Such notes require the holder to notify CCI in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. CCI has not received any written declarations of default from holders of its remaining outstanding notes payable.

During nine months ended September 30, 2010, the Company was advanced $798,000 from related parties. These advances are non-interest bearing and are due on demand.

Note 8. Stockholders’ Equity (Deficit)

Loss per share

A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows:


	Nine months ended						Three months ended
	September, 2010			September 30, 2009			September 30, 2010			September 30, 2009
	(Unaudited)						(Unaudited)

Basic and Diluted:
Net loss applicable to common stockholder	$	(1,301	)	$	(3,636	)	$	(538	)	$	(610	)
Weighted average common shares outstanding		44,939,579			41,831,056			45,477,839			42,173,810
Net loss per common share	$	(0.03	)	$	(0.09	)	$	(0.01	)	$	(0.01	)

Stock options and warrants to purchase 3,807,935 and 3,629,042 common shares and preferred stock convertible into 543,315 and 514,877 common shares were not included in the computation of diluted loss per share applicable to common stockholders as they are anti-dilutive as a result of net losses for the periods ended September 30, 2010 and September 30, 2009, respectively.

As of September 30, 2010 and 2009, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with SFAS No. 128, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation. After taking these undeclared and unpaid preferred dividends into account for the period, the net loss applicable to common stockholders for the nine and three months ended September 30, 2010 was $1,500,000 and $605,000, respectively.

Preferred Stock

A summary of the Company’s preferred stock is as follows:


	September 30,		December 31,
	2010		2009
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
	(unaudited)
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		175,000		175,000
Series E convertible, 10% cumulative dividend		19,222		19,222

Total Preferred Stock		373,555		373,555

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock


Liquidation Value:		$4.50 per share
Conversion Price:		$103.034 per share
Conversion Rate:		0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034)
Voting Rights:		None
Dividends:		None
Conversion Period:		Any time

Series B Convertible Preferred Stock


Liquidation Value:		$4.00 per share
Conversion Price:		$10.00 per share
Conversion Rate:		0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00)
Voting Rights:		None
Dividends:		10%—Quarterly—Commencing March 31, 2001
Conversion Period:		Any time

Cumulative and undeclared dividends in arrears at September 30, 2010 were $360,000

Series C Convertible Preferred Stock


Liquidation Value:		$3.00 per share
Conversion Price:		$6.00 per share
Conversion Rate:		0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00)
Voting Rights:		None
Dividends:		10%—Quarterly—Commencing March 31, 2002
Conversion Period:		Any time

Cumulative and undeclared dividends in arrears at September 30, 2010 were $103,000

Series D Convertible Preferred Stock


Liquidation Value:		$10.00 per share
Conversion Price:		$10.00 per share
Conversion Rate:		1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00)
Voting Rights:		None
Dividends:		10%—Quarterly—Commencing April 30, 2002
Conversion Period:		Any time

Cumulative and undeclared dividends in arrears at September 30, 2010 were $1,561,000

Series E Convertible Preferred Stock


Liquidation Value:		$22.00 per share
Conversion Price:		$8.00 per share
Conversion Rate:		2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00)
Voting Rights:		Equal in all respects to holders of common shares
Dividends:		10%—Quarterly—Commencing May 31, 2002
Conversion Period:		Any time

Cumulative and undeclared dividends in arrears at September 30, 2010 were $380,000

Issuance of Common Shares and Warrants for Cash

During the quarter ending June 30, 2010, the Company received proceeds of $50,000 and issued 500,000 shares of restricted unregistered common stock at a price of $0.10 per share and warrants to purchase 250,000 shares of restricted unregistered common stock at a price of $0.10 per share. The warrants have a term of three years.

In addition, the Company issued 485,000 shares of restricted unregistered common stock at a price of $0.25 per share for warrants that were exercised in 2009.

Issuance of Common Stock and Warrants as Payment for Legal Settlement

During the quarter ended March 31, 2010, a settlement agreement was approved by the court and CCI issued 2,658,800 shares of restricted unregistered common stock and a warrant to purchase 217,000 shares of restricted unregistered common stock to NeoMed Innovation III L.P. The Company valued the common stock at $0.19 per share for a total of $505,000 using fair value and the warrant at $33,000 using the Black-Scholes method. The warrant has a term of three years and is exercisable immediately. The aggregate cost totaling $538,000 was recorded as other expense in 2009.

Issuance of Common Stock as Settlement of Debt

During the quarter ending September 30, 2010, CCI issued 66,667 shares of restricted, unregistered common stock value at $0.15 per share using fair value for the settlement of debt totaling $10,000.

Issuance of Common Stock as Payment for Services

In the first quarter of 2010, CCI was required to issue 31,637 shares of restricted, unregistered common stock valued at an average $0.19 per share to a consultant as payment for services rendered. The Company recorded the value of the common stock at $6,000 and recorded the amount as a selling, general and administrative expense. The Company also issued 119,169 shares of restricted, unregistered common stock valued at an weighted average $0.19 per share to a consultant as payment for services rendered. The Company recorded the value of the common stock at $30,000 and recorded the amount as a selling, general and administrative expense in 2009 and issued the shares in the second quarter of 2010.

Issuance of Common Stock and Warrants as Compensation

During the quarter ending September 30, 2010, CCI issued warrants to a non-executive employee to purchase 2,000 shares of restricted, unregistered common stock at $0.03 per share. The warrants were valued at $34 and recorded the amount as a selling, general and administrative expense.

During the quarter ended June 30, 2010, CCI issued 100,000 shares of restricted, unregistered common stock valued at $0.15 per share to a non-executive employee. The Company recorded the value of the common stock at $15,000 and recorded the amount as a selling, general and administrative expense.

In addition, CCI issued warrants to a non-executive employee to purchase 9,000 shares of restricted, unregistered common stock at $0.10 per share. The warrants were valued at $1,000 and recorded the amount as a selling, general and administrative expense.

Application of Black-Scholes Valuation Model

In applying the Black-Scholes valuation model, the Company used the following assumptions for the three months ended September 30, 2010 and 2009:


	2010			2009
Expected volatility		240%-319	%		174%-207	%
Expected term (years)		1.5			1.5
Risk-free interest rate		1.00	%		1.00	%
Expected dividend yield		0	%		0	%
Forfeiture rate		0	%		0	%
Resulting weighted average grant date fair value		$0.15			$0.20-$0.09

Note 9. Derivative Liability

In March 2010, as discussed in Note 7. the Company issued a note with a variable conversion feature. This resulted in the Company having an aggregate number of shares of common stock issued as well as instruments convertible or exercisable into common shares that potentially may exceed the number of the Company’s total authorized common shares. Consequently, the Company is required to record a liability for the potential excess of shares over the authorized amount. The Company is required to revalue this liability no less than every quarter. The Company determined that the excess shares were related to warrants issued and outstanding as of March 31, 2010. Based upon the Financial Accounting Standards Board (FASB) guidance, the Company determined the fair value of these excess shares using the Black-Scholes valuation model. As a result, the Company recorded an initial liability of $313,000. The Company increased the liability and reduced additional paid in capital by $31,000 as a result of an additional derivative liability for new warrants. As of September 30, 2010, the Company remeasured this liability, and the Company reduced this liability to $106,000 and correspondingly recorded an unrealized benefit of $238,000. Also included in the derivative liability balance at September 30, 2010 is $55,000 from a note discounted as described in Note 7. As a result, the derivative liability has a balance of $161,000 as September 30, 2010.

Note 10. Legal Proceedings

The Company is a party to a pending legal proceeding which is described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as filed with the SEC. The Company also settled a legal proceeding during the first quarter of 2010. To the Company’s knowledge, there have been no cases initiated by or against the Company, nor any cases resolved, since the date of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 except as described herein. A summary of the pending and settled cases is as follows:

MedPlast Elkhorn, Inc. In May 2009, MedPlast Elkhorn, Inc. (“MedPlast”) filed suit against the Company in the Circuit Court, Walworth County, Wisconsin (Case No. 09 CV00721). MedPlast alleges that the Company has failed to pay for certain tools and materials used in the manufacturing of the Company’s products. MedPlast is asking for payment of $377,000. The Company believes that it has made adequate provision for any obligation to MedPlast.

Wildman, Harrold, Allen & Dixon LLP. In November 2009, Wildman, Harrold, Allen & Dixon LLP. (“Wildman”) filed suit against the Company in the Circuit Court of Cook County Illinois (Case No. 2009-L-013902). Wildman alleged that the Company failed to pay for legal services in the amount of $41,407. In January 2010, the Company entered into a Confession of Judgment and a payment plan with Wildman. The payment plan provides for an initial payment of $5,000 in January 2010, two payments of $1,500 each in February and March 2010, two payments of $2,500 each in April and May 2010, two payments of $4,000 each in June and July 2010, one payment of $10,203 in August 2010 and a final payment of $10,203 in September 2010. As of November 12, 2010, the Company has made all of the required payments.

Patricia H. Guerzo. In April 2010, Patricia H. Guerzo (“Guerzo”) doing business as Guerzo Business Solutions Center filed suit against the Company in the Circuit Court of Cook County Illinois (Case No. 2010200660). Guerzo alleged that the Company failed to pay for consulting services in the amount of $17,563.75. In May 2010, the Company entered into an agreement to make an initial payment of $2,564 and six monthly payments of $2,500. The Company has made all of the required payments to date.

Silicon Engines, Ltd. In March 2010, Silicon Engines Ltd. (“Silicon”) filed suit against the Company in the Circuit Court of Cook County Illinois (Case No. 2010 L 002923). Silicon alleged that the CCI failed to pay for services rendered in the amount of $45,908.06. In May 2010 the Company entered into an agreement to make an initial payment of $5,000, twelve monthly payments of $3,000 and a final payment of $4,908. The Company has made all of the required payments to date.

Securities and Exchange Commission Subpoenas

trading records of insiders and certain other documents relating to the Company’s operations. CCI has submitted to the SEC the requested documents. The Company does not know what, if any, action the SEC intends to take at this time.

Other claims

CCI has been a party to a number of other proceedings, informal demands, or debt for services brought by former unsecured creditors to collect past due amounts for services. CCI is attempting to settle these demands and unfilled claims. CCI does not consider any of these claims to be material.

Contingencies

The Company has not filed its income tax returns for 2008 or 2009, nor has it filed its franchise returns for 2009 or paid its franchise tax for that year.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements contained in this discussion and analysis that are not related to historical results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive, that depend upon or refer to future events or conditions, or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “hopes,” or similar expressions constitute forward-looking statements. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, or possible future actions by us are also forward-looking statements.

These forward-looking statements are based on beliefs of our management as well as current expectations, projections and information currently available to the Company and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated or implied by such forward-looking statements. These risks are described more fully in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2009 under the caption “Risk Factors”, and include our ability to raise capital; our ability to settle litigation; our ability to retain key employees; economic conditions; technological advances in the medical field; demand and market acceptance risks for new and existing products, technologies, and healthcare services; the impact of competitive products and pricing; manufacturing capacity; U.S. and international regulatory, trade, and tax policies; product development risks, including technological difficulties; ability to enforce patents; and foreseeable and unforeseeable foreign regulatory and commercialization factors.

Should one or more of such risks or uncertainties materialize or should underlying expectations, projections or assumptions prove incorrect, actual results may vary materially from those described or implied by forward- looking statements. Those events and uncertainties are difficult to predict accurately and many are beyond our control. We believe that our expectations with regard to forward-looking statements are based upon reasonable assumptions within the bounds of our current business and operational knowledge, but we cannot be sure that our actual results or performance will conform to any future results or performance expressed or implied by any forward-looking statements. We assume no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of these statements except as specifically required by law. Accordingly, past results and trends should not be used to anticipate future results or trends.

Overview of CytoCore, Inc.

Our current product which we have for sale and have inventory on hand is the SoftPAP. CCI is developing, identifying markets for and plans to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the CytoCore SolutionsÔ trade name. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), and patient treatment and monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. CCI plans that this focus will later be expanded to include other gynecological cancers as well as bladder, lung and breast cancers, among others. Within each of these markets, CCI

anticipates that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations.

The science of medical diagnostics has advanced significantly during the past decade. Much of this advance has come as a result of new knowledge of the human genome and related proteins, which form the foundation of cell biology and the functioning of the human body. Our goal is to utilize this research as a base to develop screening and diagnostic testing products for cancer and cancer-related diseases. We believe that the success of these products will improve patient care through more accurate test performance, wider product availability and more cost-effective service delivery. We have developed the SoftPAP^®, a sample collection device approved by the U.S. Food and Drug Administration, and are licensed to sell the PadKitÔ collection device and GluCyteÔ cell preservative. We are focusing on the development and testing of cocktail assay markers and stains for use with the Company’s Automated Image Proteomic System (AIPSÔ) to screen for various cancers.

Our strategy is to develop products through internal development processes, strategic partnerships, licenses and acquisitions. This strategy has required and will continue to require additional capital. As a result, we will incur substantial operating losses until we are able to successfully market our products.

The Company has incurred significant losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop, manufacture and market its products. Implementation of the Company’s plans and its ability to continue as a going concern depend upon its ability to increase sales of its products, develop new products and raise additional capital. If the Company is unable to obtain adequate additional financing or generate sufficient sales revenues, it will be unable to continue its product development efforts and other activities and will be forced to curtail or cease operations. The consolidated financial statements presented herein do not include any adjustments that might result from the outcome of this uncertainty.

Critical Accounting Policies and Changes to Accounting Policies

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

There have been no material changes in our critical accounting policies or critical accounting estimates since December 31, 2009, nor have we adopted any accounting policy that has or will have a material impact on our consolidated financial statements. For further discussion of our accounting policies see our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, including the notes to our consolidated financial statements included therewith, as filed with the SEC.

Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited consolidated financial statements presented in Part I, Item 1 of this Quarterly Report and the notes thereto, and our audited consolidated financial statements and notes thereto, as well as our Management’s Discussion and Analysis, contained in our Annual Report on Form 10-K for the year ended December 31, 2009.

Three Months Ended September 30, 2010 as compared to Three Months Ended September 30, 2009

Revenue

Revenues for the three months ended September 30, 2010 as compared with the three months ended September 30, 2009 increased $3,000, or 60%, from $5,000 to $8,000. This increase was primarily the result of a sale of preservative for use with the SoftPAP cervical collection device.

Costs and Expenses

Cost of Revenues

Cost of revenues for the quarter ended September 30, 2010 was $1,000. There was no cost of revenues for the quarter ended September 30, 2009 since we had no sales of our SoftPAP product during the quarter.

Research and Development

For the three months ended September 30, 2010, our research and development (“R&D”) expenses were $83,000, a $4,000 or 5% decrease from R&D expenses of $87,000 for the same period in 2009. This $4,000 decrease related to a reduction in payroll expenses.

R&D expenses primarily consist of costs related to specific development programs with scientists and researchers and expenses incurred by engineers and researchers at CCI’s Chicago facility.

Selling, General and Administrative

For the three months ended September 30, 2010, selling, general and administrative expenses (“SG&A”) were $495,000, a decrease of $30,000 or 6%, from SG&A expenses of $525,000 for the same period in 2009. Of this $32,000 decrease, insurance expense decreased $14,000, director fees decreased $5,000, travel expenses decrease by $7,000, franchise taxes decreased $2,000, rent expense decreased $2,000 and marketing expenses decreased $2,000. These decreases were partially offset by an increase in professional fees of $37,000 offset by a decrease of $71,000 due to a trade debt settlement, an increase of $21,000 in payroll related expenses and printing expense increased $15,000.

Other Income (Expense)

Interest expense was $23,000 for the three months ended September 30, 2010, an increase of $20,000, from interest expense of $3,000 for the same period in 2009.

During the three months ended September 30, 2010, CCI recorded a non-cash benefit of $56,000 resulting from the remeasurement of the derivative liability as described in Note 9 to the financial statements.

Net Loss

The net loss for the three month period ended September 30, 2010 totaled $538,000, as compared with $610,000 for the same period in 2009, a decrease of $72,000 or 12%. This decrease resulted from reductions in R&D and SG&A expenses due to the Company having insufficient funds to complete its business plans, partially offset by the non-cash benefit resulting from the remeasurement of the derivative liability.

The net loss per common share for each of the three month periods ended September 30, 2010 and September 30, 2009 was $0.01 per share on 45,477,839 and 42,173,810 weighted average common shares outstanding, respectively.

Nine Months Ended September 30, 2010 as compared to Nine Months Ended September 30, 2009

Revenue

Revenues for the nine months ended September 30, 2010 as compared with the nine months ended September 30, 2009 decreased $4,000, or 14%, from $28,000 to $24,000. This decrease was the result of a reduction in revenue from the licensing fees for our slide-based installed systems, partially offset by the sale of preservative for use with our SoftPAP cervical collection devise.

Costs and Expenses

Cost of Revenues

Cost of revenues for the nine months ended September 30, 2010 was $1,000 as compared to $6,000 for the same period in 2009, a decrease of $5,000 or 83%.

Research and Development

For the nine months ended September 30, 2010, our research and development (“R&D”) expenses were $213,000, an $87,000 or 29% decrease from R&D expenses of $300,000 for the same period in 2009. Of this $87,000 decrease, $82,000 related to a reduction in payroll expenses and $5,000 related to reductions in other costs.

R&D expenses primarily consist of costs related to specific development programs with scientists and researchers and expenses incurred by engineers and researchers at CCI’s Chicago facility.

Selling, General and Administrative

For the nine months ended September 30, 2010, selling, general and administrative expenses (“SG&A”) were $1,297,000, a decrease of $1,084,000 or 46%, from SG&A expenses of $2,381,000 for the same period in 2009. Of this $1,084,000 decrease, director fees decreased $335,000, payroll related expenses decreased $172,000 due in part to the reversal of a $125,000 accrual, professional fees decreased $279,000 in addition to a trade debt settlement of $71,000, printing expense decreased $19,000, franchise taxes decreased $73,000, travel expense decreased $35,000, rent expense decreased $16,000, transfer agent fees decreased $8,000, marketing expenses decreased $26,000, insurance expense decreased $44,000 and investor relations expenses decreased $35,000. These decreases were partially offset by an increase in depreciation expense of $15,000, an increase in financing costs of $9,000 and increases in other costs of $5,000.

Other Income (Expense)

Interest expense was $52,000 for the nine months ended September 30, 2010, an increase of $23,000, from interest expense of $29,000 for the same period in 2009.

During the nine months ended September 30, 2010, CCI recorded a non-cash benefit of $238,000 resulting from the remeasurement of the derivative liability as described in Note 9 to the financial statements, and $41,000 from the amortization of debt discount.

During the six months ended June 30, 2009, the Company recorded a non-cash charge of $948,000 to reflect a preliminary legal settlement.

Net Loss

The net loss for the nine month period ended September 30, 2010 totaled $1,301,000, as compared with $3,636,000 for the same period in 2009, a decrease of $2, 335,000 or 64%. Of this decrease, $948,000 resulted from a non-cash charge for a legal settlement and reductions in R&D and SG&A expenses due to the Company having insufficient funds to complete its business plans, partially offset by the non-cash benefit resulting from the remeasurement of the derivative liability.

The net loss per common share for each of the nine month periods ended September 30, 2010 and September 30, 2009 was $0.03 and $0.09 per share on 44,939,579 and 41,925,232 weighted average common shares outstanding, respectively.

Liquidity and Capital Resources

To date, the Company’s capital resources and liquidity have been generated primarily from investments by individual and institutional investors.

Research and development, clinical trials and other studies of the components of our CytoCore Solutions System, conversions from designs and prototypes into products and product manufacturing, sales and marketing efforts, medical consultants and advisors, and research, administrative and executive personnel are and will continue to be the principal basis for our cash requirements. CCI has provided operating funds for the business since its inception through private offerings of debt and equity securities to U.S. accredited and foreign investors. In order to

generate cash in the next twelve months, the Company will be required to make additional private offerings of debt or equity, or discount its product in order to generate sales to support the operations of the business until some or all of our products are successfully marketed. We used $881,000 for the nine months ended September 30, 2010 in operating activities. During the nine months ending September 30, 2010, approximately $213,000 was spent on R&D and approximately $1,297,000 was spent on SG&A functions.

During the nine months ended September 30, 2010, the Company invested $36,000 for the purchase of a license. CCI is obligated to make additional payments for this license totaling $64,000. The Company has no other material commitments at this time for capital expenditures during the remainder of the 2010 fiscal year.

We were able to raise proceeds of $923,000 through advances from related parties totaling $798,000 and the issuance of a $75,000 convertible note payable and the sale of 500,000 shares of restricted, unregistered common stock for $50,000 during the nine months ended September 30, 2010. The proceeds were used to satisfy certain present and past obligations. At September 30, 2010, the Company had $6,000 on hand. At September 30, 2010, the Company’s cash balance was not sufficient to fund its operations.

We have incurred significant operating losses since inception of the business. We expect that on-going operating expenditures will be necessary to successfully implement our business plan and develop, manufacture and market our products. Our operations have been, and will continue to be until we are able to generate significant product revenues, dependent upon management’s ability to raise funds from the sale of our securities. There can be no assurance that we will be able to obtain additional capital to meet our current operating needs or to complete pending or contemplated licenses or acquisitions of technologies. If we are unable to raise sufficient adequate additional capital or generate profitable sales revenues, we will be forced to substantially curtail product research, development and other activities, and will be forced to cease operations.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risks

The Company is exposed to market risk in the normal course of its business operations, including the risk of loss arising from adverse changes in interest rates and foreign exchange rates. The Company does not enter into derivatives or other financial instruments for trading or speculative purposes, or engage in any hedging activities.

We are headquartered in the United States where we conduct the majority of our business activities, although we do have distribution agreements with several distributors in Europe. We have not to date had any material exposure to foreign currency rate fluctuations. Nevertheless, because a portion of the Company’s revenues may be generated outside of the United States in currencies other than the United States dollar, the Company’s operations may be subject to changes in foreign exchange rates and changes in the value of the United States dollar against other currencies, which changes could affect the Company’s net earnings.

As of September 30, 2010, we had total debt of $199,000, of which $111,000 bears interest at fixed interest rates and $34,000 bears interest at a variable rate. As of September 30, 2010, we had approximately $6,000 of cash, cash equivalents or short-term investments. Due to the nature of our short-term investments and our lack of material long-term debt, we do not believe that we currently face any material interest risk exposure.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our chief executive officer, who is also the Company’s chief financial officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, our chief executive and chief financial officer has concluded that our current disclosure controls and procedures are effective to ensure that such officer is provided with information related to the Company to allow timely decisions regarding information required to be disclosed in the reports filed or submitted by CCI under the Exchange Act and that such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

Securities and Exchange Commission Subpoenas

SEC action. The Company received subpoenas dated June 29, 2009, July 24, 2009 and March 2, 2010 (the “Subpoenas”) from the Securities and Exchange Commission (the “SEC”). The Subpoenas request documents pertinent to the Company’s procedures to raise equity in 2008 and 2009, as well as personal information including trading records of insiders and certain other documents relating to the Company’s operations. CCI has submitted to the SEC the requested documents. The Company does not know what, if any, action the SEC intends to take at this time.

Other claims

Contingencies

The Company has not filed its income tax returns for 2008 or 2009, nor has it filed its franchise returns for 2009 or paid its franchise tax for that year.

Item 1A. Risk Factors.

During the first nine months of 2010, there were no material changes to the Company’s risk factors as described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as filed with the SEC. The discussion of the risks facing the Company appears in Item 1A under the caption “Risk Factors.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

Issuance of Common Shares and Warrants for Cash

In addition, the Company issued 485,000 shares of restricted unregistered common stock at a price of $0.25 per share for warrants that were exercised in 2009.

Issuance of Common Stock and Warrants as Payment for Legal Settlement

Issuance of Common Stock as Settlement of Debt

During the quarter ending September 30, 2010, CCI issued 66,667 shares of restricted, unregistered common stock value at $0.15 per share using fair value for the settlement of debt totaling $10,000.

Issuance of Common Stock as Payment for Services

Issuance of Common Stock and Warrants as Compensation

Exemptions

CCI issues securities in reliance on the safe harbor and exemptions from registration provided under Rule 506 of Regulation D and/or Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offerings and sales or issuances were made to a limited number of persons, and transfer was restricted by the Company in accordance with the requirements of applicable law. In addition to representations by the above-referenced persons, the Company has made independent determinations that investors were accredited or sophisticated, that they were capable of analyzing the merits and risks of their investment, and that they understood the speculative nature of their investment. Furthermore, these investors were provided with access to CCI’s SEC filings.

Company Repurchases of Securities

During the nine months ended September 30, 2010, neither the Company nor any affiliated purchaser of the Company purchased equity securities of CCI.

Item 3. Defaults upon Senior Securities

As of September 30, 2010, CCI had failed to make the required principal and interest payments, constituting events of default, on the $21,000 Ventana Medical Systems, Inc. promissory note.

The note requires the holder to notify CCI in writing of a declaration of default at which time a cure period, as specified in the note, would commence. There is no guarantee that CCI would be able to cure any event of default if, or when, the holder provides the required written notice. CCI has not received any written declarations of default from holders of remaining outstanding notes payable during the nine months ended September 30, 2010.

Item 4. Reserved

Item 5. Other Information

None.

Item 6. Exhibits

See Exhibit Index.


	CytoCore, Inc.
	/s/ Robert F. McCullough, Jr.
	Robert F. McCullough, Jr.
	Chief Executive Officer and Chief Financial Officer


Exhibit
Number		Description

31		Section 302 certification by principal executive and chief financial officer.

32		Section 906 certification by principal executive and chief financial officer.

(1)		I have reviewed this quarterly report on Form 10-Q of CytoCore, Inc.;

(2)		Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)		Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)		I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.		designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b.		designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.		evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.		disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)		I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.		all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.		any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents


		Page
PART I. — FINANCIAL INFORMATION
Item 1.	Financial Statements
	a) Condensed Consolidated Balance Sheets — September 30, 2010 and December 31, 2009 (unaudited)		2
	b) Condensed Consolidated Statements of Operations — Nine and Three months ended September 30, 2010 and September 30, 2009 (unaudited)		3
	c) Condensed Consolidated Statements of Cash Flows — Nine months ended September 30, 2010 and September 30, 2009 (unaudited)		4
	d) Notes to Unaudited Condensed Consolidated Financial Statements		5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		11
Item 3.	Quantitative and Qualitative Disclosures about Market Risk		16
Item 4.	Controls and Procedures		16
PART II. — OTHER INFORMATION
Item 1.	Legal Proceedings		16
Item 1A.	Risk Factors		17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		18
Item 3.	Defaults upon Senior Securities		19
Item 4.	Reserved		19
Item 5.	Other Information		19
Item 6.	Exhibits		19
SIGNATURES			20
EXHIBIT INDEX			21
Exhibit 31	Section 302 Certification
Exhibit 32	Section 906 Certification
EX-31
EX-32



	/s/ Robert F. McCullough Jr.
	Robert F. McCullough Jr.
	Chief Executive Officer and Chief Financial Officer Dated: November 19, 2010